BLCM +9% on BPX-501 clinical-hold update: https://finance.yahoo.com/news/bellicum-announces-clinical-hold-u-120000591.html To address the FDA requirements, the Company plans to implement revisions to the U.S. study protocols, including the addition of more comprehensive monitoring and management of neurotoxicity. In addition, the Company will revise the Investigator Brochure and Informed Consent Documents to inform healthcare providers, patients and caregivers of the changes. The Company expects to provide a full response to the FDA within a few weeks. The hold itself has not yet been lifted.